| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
We demonstrated that incretin, such as gastric inhibitory polypeptide and glucagon-like peptide-1, had no effects on the differentiation and mineralization of mesenchymal stem cell-like ST2 cells and osteoblastic MC3T3-E1 cells as well as the expression of RANKL in osteocytic MLO-Y4 cells. Moreover, bone volume and bone strength were not different between C57BL mice with and without administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor. In a clinical study, elevated serum DPP-4 levels were significantly and positively associated with the presence of metabolic syndrome in men with type 2 diabetes. In addition, increased serum DPP-4 levels were significantly associated with the risk of multiple vertebral fractures through bone resorption in the population.
|
